It yielded myocardial T-1 values consistent with expected T-1 and an increasing homogenization of myocardial segments owing to B-1 correction. The mean myocardial T-1 value was 134142 ms.\n\nConclusionMyocardial 3D T-1 mapping using the variable flip angle approach can potentially be useful for evaluating FK228 cost fibrosis on the entire myocardium using a standard clinical sequence. Magn Reson Med 71:823-829, 2014. (c) 2013 Wiley Periodicals, Inc.”
“Background: Acute hyperglycaemia is an adverse prognostic factor
in patients with acute coronary syndrome (ACS). It is unclear whether these negative effects apply equally to patients with diabetes mellitus (DM) and non-DM patients.\n\nAim: To evaluate the short-term (in-hospital) and long-term (four-year) prognostic value of acute hyperglycaemia in ACS patients with or without DM.\n\nMethods: The study involved 116 ACS patients admitted between 2004 and 2006 to our department, who were learn more selected for invasive treatment and who had both admission and first fasting glucose levels measured. Patients were classified as DM (n = 23), on the basis of a known history of diabetes or newly detected diabetes, or non-DM (n = 93). Acute hyperglycaemia was defined as an
admission glycaemia >= 10.0 mmol/L (180 mg/dL) for non-DM patients, or >= 7.8 mmol/L (140 mg/dL) for DM patients, or a first fasting glucose level >= 5.6 mmol/L (100 mg/dL) for both DM and selleck screening library non-DM patients. The primary end-point was defined as mortality during follow-up. The secondary end-points were death, cardiac arrest or repeated ACS occurrence, stroke or transient ischaemic attack, and the need for repeat percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) procedure during the in-hospital and four-year
post-hospital periods. During follow-up, patients were assessed for a composite end-point defined as all-cause death, repeated ACS occurrence, repeat PCI or CABG procedure, and stroke.\n\nResults: Acute hyperglycaemia was present in 28 non-DM and 14 DM patients. The mean follow-up time was 4 +/- 0.6 years. For DM patients, there was no significant difference in four-year mortality between hyperglycaemic and normoglycaemic patients (14.3% vs 11.1%, respectively; NS). The occurrence of secondary end-points and composite end-point frequency was also similar for these subgroups, both for in-hospital and four-year observations. For non-DM patients, the four-year mortality was similar for hyperglycaemic and normoglycaemic subjects (17.9% vs 10.8%, respectively; NS), whereas cardiac arrest during the in-hospital period was more common for hyperglycaemic than normoglycaemic patients (3.6% vs 0.0%, respectively; n = 1 vs 0; p = 0.01). The composite end-point for the in-hospital period was reached by 17.6% of hyperglycaemic and 13.